For Healthcare Professionals Outside the US
BRAF mutational testing should be mandatory in patients with advanced disease2 as stated by the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Cutaneous Melanoma
Long GV, et al. J Clin Oncol. 2011;29(10):1239-1246. Reprinted with permission. © 2011 American Society of Clinical Oncology. All rights reserved.
ERK, extracellular signal–regulated kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; OS, overall survival; WT, wild type.
References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 2. Dummer R, Hauschild A, Lindenblatt N, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v126-v132. 3. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239-1246. 4. Hugdahl E, Kalvenes MB, Puntervoll HE, Ladstein RG, Akslen LA. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. Br J Cancer. 2016;114(7):801-808.